Mueller Brian 4
4 · BIOMARIN PHARMACEUTICAL INC · Filed Feb 26, 2026
Research Summary
AI-generated summary of this filing
BioMarin (BMRN) CFO Brian Mueller Receives RSU Award
What Happened
Brian Mueller, Chief Financial Officer of BioMarin Pharmaceutical (BMRN), was certified on Feb 25, 2026 as having earned three performance-based restricted stock unit (RSU) awards totaling 16,482 RSUs (6,683; 7,230; 2,569). The Form 4 reports these as awards/acquisitions at a reported price of $0.00 (grant), i.e., no cash paid at grant. The RSUs convert on a 1:1 basis to common shares when they vest.
Key Details
- Transaction date: 2026-02-25 (Form 4 filed 2026-02-26 — appears timely). Transaction code: A (award/grant). Reported price per share: $0.00. Total RSUs: 16,482.
- Vesting: RSUs were earned (certified) but vest on March 15, 2026, subject to Mueller’s continued service through that date and certain acceleration events (see footnote F3).
- Why earned: Awards are performance-based — portions were earned based on relative total shareholder return (F2), development goals achieved (F4), and core operating margin metrics (F5) covering 2023–2025.
- Conversion: RSUs convert 1:1 into common stock when vested (F1).
- Shares owned after transaction: not stated in the provided filing excerpt.
- No sale or exercise reported — these are awards, not an open-market purchase or disposition.
Context
Performance-based RSUs reflect formulaic payouts tied to company metrics and are different from open-market purchases or sales. They don’t by themselves indicate an insider’s near-term buying or selling intent; they represent compensation earned under pre-established plans and will only become marketable shares if/when they vest (and any applicable tax withholding is satisfied).
Insider Transaction Report
- Award
Common Stock
[F1][F2][F3]2026-02-25+6,683→ 106,839 total - Award
Common Stock
[F1][F3][F4]2026-02-25+7,230→ 114,069 total - Award
Common Stock
[F1][F3][F5]2026-02-25+2,569→ 116,638 total
Footnotes (5)
- [F1]Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis.
- [F2]Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.
- [F3]Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2026, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events.
- [F4]Represents the total number of RSUs earned pursuant to a formula based on the number and nature of development goals achieved during 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.
- [F5]Represents the total number of RSUs earned pursuant to a formula based on core operating margin over three, one-year periods spanning 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.